AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Vertex Pharmaceuticals (VRTX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

461.93

2.93 (0.64%)

At close: Feb 18, 2025, 3:59 PM

462.11

0.04%

After-hours: Feb 18, 2025, 04:11 PM EST

undefined% (undefined)

Bid	455.75
Market Cap	118.62B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.07
PE Ratio (ttm)	-223.15
Forward PE	n/a
Analyst	Buy

Ask	468
Volume	912,542
Avg. Volume (20D)	1,644,610
Open	455.06
Previous Close	459.00
Day's Range	451.99 - 465.12
52-Week Range	377.85 - 519.88
Beta	undefined

About VRTX

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 24, 1991

Employees 6,100

Stock Exchange NASDAQ

Ticker Symbol VRTX

Website https://www.vrtx.com

Full Company Profile

Analyst Forecast

According to 25 analyst ratings, the average rating for VRTX stock is "Buy." The 12-month stock price forecast is $520, which is an increase of 12.57% from the latest price.

Buy 64.00%

Hold 36.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Vertex Pharmaceuticals is scheduled to release its earnings on May 5, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

+5.31%

Vertex Pharmaceuticals shares are trading higher a... Unlock content with Pro Subscription

2 months ago

-11.37%

Vertex Pharmaceuticals shares are trading lower. The company announced results from its Phase 2 study of Suzetrigine.

News

1 day ago · businesswire.com

Vertex to Participate in Upcoming March Investor Conferences

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Stuart Arbuckle, Executive Vice President a...

20 hours ago · cnbc.com

High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models

Deshawn "DJ" Chow is one of just over 100 sickle cell patients who have undergone treatment with new gene therapies. CVS Health CEO David Joyner said private insurers and employer-sponsored health pla...

2 days ago · fool.com

3 Stocks That Could Trounce the Market in 2025

If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch.

3 days ago · fool.com

2 Healthcare Stocks That Tumbled in 2024

Vertex Pharmaceuticals (VRTX -0.77%) and AstraZeneca (AZN -1.17%), two of the world's leading drugmakers, missed last year's strong market rally. Both finished 2024 slightly in the red.

4 days ago · zacks.com

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

4 days ago · accessnewswire.com

Levi & Korsinsky Announces an Investigation on Behalf of Vertex Pharmaceuticals Incorporated (VRTX) Shareholders Who May Have Been Affected by Fraud

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDA...

5 days ago · fool.com

The Ultimate Healthcare Stock to Buy With $500 Right Now

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare stocks as a group are barely in positive territory.

5 days ago · fool.com

Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business.

5 days ago · accessnewswire.com

Vertex Pharmaceuticals Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VRTX

NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDA...

1 week ago · youtube.com

Calls of the Day: Charles Schwab, Vertex Pharma and Transocean

The Investment Committee debate the latest Calls of the Day.

Load More News